miR-551b-3p was under-expressed in CCA tissues compared to normal bile duct tissues. Furthermore, our data confirmed the decreased levels of miR-551b-3p in CCA samples and cell lines. Interestingly, TCGA data suggested that low miR-551b-3p level indicated reduced overall survival of CCA patients. Gain-and loss-of-function experiments found that miR-551b-3p inhibited the proliferation, G1-S phase transition and induced apoptosis of CCA cells. In vivo experiments revealed that ectopic expression of miR-551b-3p inhibited tumour growth of CCA in mice. Further investigation demonstrated that miR-551b-3p directly bond to the 3′-UTR of Cyclin D1 (CCND1) mRNA and negatively regulated the abundance of CCND1 in CCA cells. An inverse correlation between miR-551b-3p expression and the level of CCND1 mRNA was detected in CCA tissues from TCGA dataset. Notably, CCND1 knockdown showed similar effects to miR-551b-3p overexpression in HuCCT-1 cells. CCND1 restoration rescued miR-551b-3p-induced inhibition of proliferation, G1 phase arrest and apoptosis in HuCCT-1 cells. In summary, miR-551b-3p inhibits the expression of CCND1 to suppress CCA cell proliferation and induce apoptosis, which may provide a theoretical basis for improving CCA treatment.
K E Y W O R D S
cholangiocarcinoma, Cyclin D1, microRNA-551b-3p, tumour growth MicroRNAs (miRNAs), important regulators of gene expression at post-transcriptional level, exert their functions by directly binding to 3′-untranslated region (3′-UTR) of mRNAs, and subsequently regulate numerous biological and pathological processes, such as cell cycle progression, cell proliferation, apoptosis and differentiation. Increasing researches have revealed that aberrant miRNA levels are confirmed in various types of human cancer including CCA and play critical roles in the tumorigenesis and metastasis. [3] [4] [5] [6] The levels of miR-433 and miR- 22 12 Recently, a study reports that miR-551b-3p is reversely regulated by long non-coding RNA (lncRNA) SMARCC2
and mediates the tumour promoting role of SMARCC2 through regulating transmembrane serine protease 4 (TMPRSS4) in gastric cancer. 13 However, the functional role of miR-551b-3p and its underlying molecular mechanism in the tumorigenesis of CCA remain largely unclear.
This study explored the expression, functional role and potential mechanism of miR-551b-3p in CCA. Overexpression of miR-551b-3p
inhibited CCA cell proliferation and resulted in cell cycle arrest at G1 phase and apoptosis by targeting Cyclin D1 (CCND1), which might benefit for finding new treatment modalities to improve prevention and treatment of CCA.
| MATERIAL S AND ME THODS

| Patients and tissue samples
The current research was approved by the Research Ethics 
| CCA cell lines
HuCCT-1, RBE, HCCC-9810, QBC939 cell lines and the human intrahepatic biliary epithelial cell line (HiBEC) were maintained in our laboratory. 9 Cells were cultured in high-glucose DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) added with 10% FBS (Gibco), 1% penicillin (Gibco) and 100 μg/mL streptomycin (Gibco) in a humidified incubator containing 5% CO 2 at 37°C.
| Cell transfection
Vectors mediated miR-551b-3p and miR-551b-3p inhibitors 
| RNA extraction and qRT-PCR
Total RNA samples were isolated from the collected tissues and cells, respectively. RNA extraction was performed with Trizol reagent (Invitrogen) according to the manufacturer's protocols.
Then the RNA sample was reversely transcribed to cDNA using a TIANScript RT Kit (Tiangen Biotech, Beijing, China). qRT-PCR was carried out using a SYBR Green PCR Kit (Takara, Shiga, Japan) on Applied Biosystems StepOne-Plus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). GAPDH and U6 were employed as internal controls for CCND1 mRNA and miR-551b-3p, respectively. qRT-PCR primers for U6 (HmiRQP9001) and hsa-miR-551b-3p (HmiRQP0651) were obtained from Genecopoeia. CCND1 primers:
forward 5′-CGT GGC CTC TAA GAT GAA GG-3′ and reverse 5′-CTG GCA TTT TGG AGA GGA AG-3′. GAPDH primers: forward 5′-TCA GTG GTG GAC CTG ACC TG-3′ and reverse 5′-TGC TGT AGC CAA ATT CGT TG-3′. U6 primers: RT 5′-AAC GCT TCA CGA ATT TGC GT-3′, forward 5′-GCT TCG GCA GCA CAT ATA CTA AAA T-3′ and reverse 5′-CGC TTC ACG AAT TTG CGT GTC AT-3′. Has-miR-551b-3p primers: RT 5′-GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC TGA AA-3′, forward 5′-GAT ATG CGA CCC ATA CTT GG-3′ and reverse 5′-GTG CAG GGT CCG AGG T-3′.
| Cell proliferation analysis
Cell proliferation was detected using Cell Counting Kit-8 (CCK-8) and
EdU assay. CCK-8 solution (10 μL; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) and EdU (50 μmol/L; RiboBio Biotechnology, Guangzhou, China) were used for these assays as previously described. 
| Apoptosis analysis
For apoptosis analysis, the PE Annexin V Apoptosis Detection Kit I (BD Biosciences) was used following the manufacturer's protocols. Cells were harvested and washed with pre-cold PBS buffer twice. Then, 5 μL of PE Annexin V and 5 μL of 7-AAD solution were added to each sample, and cells were incubated for 15 minutes at RT. FACSCanto II flow cytometer was used to measure the cell apoptosis.
| In vivo tumour xenograft experiments
In vivo tumour xenograft experiments were performed with 10 
| Dual luciferase reporter gene assay
Wild-type (wt) 3′-UTR of CCND1 and mutant type (mt) 3′-UTR of CCND1 were sub-cloned into PmirGLO plasmid (Promega, Madison, WI, USA). pmirGLO-CCND1-wt/-mt and miR-551b-3p mimics/inhibitors were co-transfected into HuCCT-1 cells. The fluorescence intensity was detected by a dual-Luciferase reporter assay system (Promega) after 24 hours of transfection. and β-actin primary antibody (Abcam) overnight at 4°C. Next, the membranes were incubated with HRP-conjugated IgG secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1-2 hours. Then, protein expression levels were detected by ECL (Millipore).
| Western blot assay
| Statistical analysis
The statistical analyses were carried out using the software of GraphPad Prism version 6.0 (GraphPad Inc., San Diego, CA, USA).
The Student's t test and ANOVA were used to compare the statistical differences between groups. A P < 0.05 was considered to indicate a significant difference.
| RE SULTS
| miR-551b-3p is down-regulated in CCA
We explored miR-551b-3p expression in TCGA Data Portal from starBase V3.0, 14 the data discovered that the level of miR-551b-3p
was down-regulated in CCA samples compared to normal bile duct tissues (P = 0.00041, Figure 1A ). Further analysis of miR-551b-3p expression in CCA samples from our hospital suggested that miR-551b-3p expression was reduced in CCA samples compared to normal bile duct tissues (P = 0.0080, Figure 1B Figure 1D ). Thus, our results suggested that miR-551b-3p might play a key role in CCA progression.
| miR-551b-3p regulates the proliferation, cell cycle progression and apoptosis of CCA cells
Further experiments were carried out to clarify the function of miR-551b-3p in CCA cells. Forced expression of miR-551b-3p was performed in HuCCT-1 and QBC939 cells (P < 0.05, Figure 2A ).
CCK-8 and EdU assays clarified that miR-551b-3p overexpres-
sion markedly restrained the proliferation of CCA cells (P < 0.05, Figure 2B and C). Flow cytometry measurement showed that the percentage of apoptotic CCA cells was markedly elevated by miR-551b-3p overexpression (P < 0.05, Figure 2D ). miR-551b-3p overexpression led to cell cycle arrest at G1 phase in HuCCT-1 and QBC939 cells (P < 0.05, Figure 2E ). Conversely, miR-551b-3p knockdown evidently enhanced RBE cell proliferation and G1-S phase transition, and reduced apoptosis in vitro (P < 0.05, Figure 3A -E). These findings indicated that miR-551b-3p inhibited the progression of CCA by inducing growth arrest and apoptosis.
| miR-551b-3p overexpression represses tumour growth of CCA in mice
To further confirm the anti-tumour role of miR-551b-3p in vivo, a subcutaneous tumour formation model was constructed using HuCCT-1 cells with or without miR-551b-3p overexpression. Notably, the tumour size and tumour weight in miR-551b-3p group were markedly less than those in control group (P < 0.05, Figure 4A ). The expression of miR-551b-3p in xenograft tumour tissues from miR-551b-3p group was markedly higher than that in control group (P < 0.05, Figure 4B ). Moreover, the rate of Ki-67 positive tumour cells in miR-551b-3p group was prominently lower as compared with that in control group (P < 0.05, Figure 4C ). Taken together, miR-551b-3p acted as a tumour suppressive factor in CCA.
| CCND1 is a downstream target of miR-551b-3p
According to the online analysis with bioinformatics database (starBase V3.0 14 ), there was a specific binding region between the 3′UTR of CCND1 and miR-551b-3p, and CCND1 was predicted to be a potential target of miR-55b-3p ( Figure 5A ). Pan-Cancer CoExpression Analysis for the miRNA-target interactions across 32 types of cancers from starBase V3.0 14 revealed that miR-551b-3p level was significantly inversely correlated with the level of CCND1 mRNA in CCA samples (r = −0.367, P = 0.0275, Figure 5B ). Notably, miR-551b-3p overexpression markedly decreased the levels of CCND1 mRNA and protein in HuCCT-1 and QBC939 cells (P < 0.05, Figure 5C ). While, miR-551b-3p knockdown prominently increased the abundance of CCND1 in RBE cells (P < 0.05, Figure 5D ). The expression of CCND1 protein in xenograft tumour tissues from miR-551-3p group was significantly lower than that in control group (P < 0.05, Figure 5E ). Next, we found that the fluorescence intensity was decreased in cells co-transfected with miR-551b-3p mimics and wt 3′UTR of CCND1, whereas enhanced in cells co-transfected with miR-551b-3p inhibitors and wt 3′UTR of CCND1 (P < 0.05, Figure 5F ). However, no noticeable difference was observed in fluorescence intensity of cells co-transfected with miR-551b-3p
The expression of miR-551b-3p in CCA. A, CCA samples (n = 36) and normal bile duct tissues (n = 9) in TCGA dataset from starBase V3.0 platform showed that miR-551b-3p expression was significantly down-regulated in tumour tissues. B, The expression of miR-551b-3p was detected in CCA tissues (n = 15) and normal bile duct tissues (n = 15) using qRT-PCR. C, The levels of miR-551b-3p between CCA cell lines (HuCCT-1, RBE, HCCC-9810 and QBC939) and HiBEC cells were analysed by qRT-PCR. *P < 0.05. C, TCGA data from starBase V3.0 platform indicated that CCA patients with low miR-551b-3p level had an obvious poorer overall survival compared to miR-551b-3p high-expressing patients mimics/inhibitors and mt 3′UTR of CCND1 ( Figure 5F ). These data displayed that CCND1 was a direct target of miR-551b-3p.
| miR-551b-3p inhibits the growth of HuCCT-1 cells through inhibiting CCND1
CCND1 knockdown was performed with a specific siRNA in
HuCCT-1 cells (P < 0.05, Figure 6A ). Notably, CCND1 knockdown significantly induced inhibition of proliferation, G1 phase arrest and apoptosis in HuCCT-1 cells (P < 0.05, Figure 6B -E), which was consistent with the effects of miR-551b-3p overexpression. Accordingly, CCND1 expression was rescued by plasmid transfection in HuCCT-1 cells with miR-551b-3p overexpression (P < 0.05, Figure 7A ). Then,
CCK-8 and EdU assays demonstrated that CCND1 restoration sig-
nificantly enhanced the proliferation of miR-551b-3p overexpressing HuCCT-1 cells (P < 0.05, Figure 7B and C). CCND1 restoration F I G U R E 2 miR-551b-3p overexpression suppresses proliferation, cell cycle progression and induces apoptosis of CCA cells. A, Vectors containing miR-551b-3p or control mimics were transfected into HuCCT1 and QBC939 cells and detected by qRT-PCR for miR-551b-3p expression. B and C, CCK-8 and EdU assays demonstrated that miR-551b-3p overexpression inhibited CCA cell proliferation. D, miR-551b-3p overexpression induced the apoptosis of CCA cells as suggested by flow cytometry analysis. E, The G1 to S phase transition was blocked by miR-551b-3p overexpression in HuCCT1 and QBC939 cells. *P < 0.05 F I G U R E 3 miR-551b-3p knockdown enhances proliferation, cell cycle progression and inhibits apoptosis of RBE cells. A, Vectors containing miR-551b-3p inhibitors or negative control (NC) were transduced into RBE cells and detected for miR-551b-3p expression using qRT-PCR. B and C, CCK-8 and EdU assays demonstrated that miR-551b-3p knockdown enhanced CCA cell proliferation. D, miR-551b-3p knockdown inhibited the apoptosis of RBE cells as suggested by flow cytometry analysis. E, miR-551b-3p knockdown facilitated the G1 to S phase transition in RBE cells. *P < 0.05 rescued miR-551b-3p induced G1 phase arrest and apoptosis in
HuCCT-1 cells (P < 0.05, Figure 7D and E). These results indicated that miR-551b-3p suppressed CCND1 expression and thereby repressed tumour growth of CCA.
| D ISCUSS I ON
Despite many studies have demonstrated the critical role of miR-551b-3p in the pathogenesis of human cancers, the expression and functional role of miR-551b-3p in CCA remain unknown.
Overexpression of miR-551b-3p is confirmed in PTC and OVCa, 10, 11 and underexpression of miR-551b-3p is detected in gastric cancer. 12, 13 This study confirmed that miR-551b-3p was under-expressed in CCA tissues and cell lines. A recent study has revealed potential mechanism involved in aberrant expression of miR-551b-3p in gastric cancer. LncRNA SMARCC2 functions as a competing endogenous RNA (ceRNA) to inversely regulate miR-551b-3p abundance in gastric cancer. 13 Furthermore, hypermethylation may be implicated in repressed expression of miR-551b in breast cancer. 15 Thus, it is worth to further investigate whether lncRNA or hypermethylation contributes to down-regulation of miR-551b-3p expression in CCA. Interestingly, TCGA data indicated that lower expression of miR-551b-3p potentially predicted a poorer overall survival of CCA patients. Previous study demonstrates that low miR-551b-3p expression indicates a poor prognosis of patients with gastric cancer. 12 Moreover, reduced miR-551b level confers to shorter survival of patients with lung adenocarcinoma. 16 Thereby, more CCA sample is required to further confirm the prognostic value of miR-551b-3p.
Increasing evidence has demonstrated that miRNAs are important drivers for tumour growth and metastasis of CCA. miR-191 plays a tumour promoting role in CCA by facilitating cell invasion, migration and proliferation. 17 Increased level of miR-181c contributes to chemoresistance, proliferation and metastasis of CCA cells. 18 Moreover, nanoparticles-delivered miR-210 inhibitors show markedly anti-tumour effects on CCA cells. 19 Functionally, miR-551b-3p
facilitates tumour growth, migration and invasion via down-regulating FOXO3 and TRIM31 in OVCa. showed subtle but significant effects in RBE cells. In addition, we recognized CCND1 as a direct target of miR-551b-3p in CCA cells.
CCND1 is an important G1-S modulator to promote rapid progression from G1 to S phase and facilitates the proliferation of CCA showed similar effects with miR-551b-3p overexpression on CCA F I G U R E 4 miR-551b-3p restoration restrains tumour growth of HuCCT-1 cells. A, HuCCT-1 cells that were transfected with vectors containing miR-551b-3p or control mimics were subcutaneously implanted into nude mice . Both tumour volume and tumour weight in miR-551b-3p group were obviously less than those in control group. B, The expression of miR-551b-3p in xenograft tumour tissues from miR-551b-3p group was significantly higher than that in control group. C, IHC analysis showed that strong staining of Ki-67 was observed in most of tumour cells in control group, whereas only several tumour cells showed weak staining of Ki-67 in miR-551b-3p group. *P < 0.05 cells. And co-transfection of CCND1 abrogated the tumour suppressive role of miR-551b-3p overexpression in CCA cells. These findings support that miR-551b-3p plays a tumour suppressive role in CCA, at least partly, via directly targeting CCND1.
In summary, we demonstrated for the first time that miR-551b-3p
was low-expressed in CCA. Functionally, miR-551b-3p inhibited cell proliferation, suppressed cell cycle progression and induced apoptosis by repressing CCND1 in CCA. Thus, miR-551b-3p may be a potential therapeutic target for CCA.
| CON CLUS IONS
To conclude, we have demonstrated that down-regulation of miR-551b-3p is a frequent event in CCA. miR-551b-3p underexpression is potentially associated with poor survival of CCA patients.
miR-551b-3p inhibits CCA cell proliferation, suppressed cell cycle progression and induces apoptosis in vitro and in vivo. CCND1 is a novel downstream target of miR-551b-3p and mediates the tumour suppressive role of miR-551b-3p. Our results may provide a novel F I G U R E 5 CCND1 is recognized as a target of miR-551b-3p in CCA cells. A, Bioinformatic analysis in starBase V3.0 platform indicated the potential binding sequences between miR-551b-3p and 3′UTR of CCND1. B, TCGA data from starBase V3.0 platform indicated that the expression of miR-551b-3p was negatively correlated with the level of CCND1 mRNA in CCA tissues. C, miR-551b-3p or control mimics were transfected into HuCCT-1 and QBC939 cells and detected for CCND1 expression using qRT-PCR and immunoblotting. D, miR-551b-3p inhibitors or negative control (NC) was transduced into RBE cells and detected for CCND1 expression using qRT-PCR and immunoblotting. E, The expression of CCND1 protein in xenograft tumour tissues from miR-551b-3p group was significantly lower than that in control group. (F) Co-transfection of miR-551b-3p mimics/inhibitors and wild-type (wt) or mutated (mt) 3′UTR of CCND1 was performed in HuCCT-1 cells and the relative luciferase activity was measured. *P < 0.05
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